Dyspnea - Pipeline Review, H2 2012

Global Markets Direct, December 2012, Pages: 27

Dyspnea – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Dyspnea - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dyspnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyspnea. Dyspnea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dyspnea.
- A review of the Dyspnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dyspnea pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dyspnea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dyspnea pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Dyspnea Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Dyspnea 6
Dyspnea Therapeutics under Investigation by Universities/Institutes 8
Late Stage Products 9
Comparative Analysis 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Dyspnea Therapeutics – Products under Investigation by Universities/Institutes 11
Dyspnea – Therapeutics Assessment 12
Assessment by Monotherapy Products 12
Assessment by Combination Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Drug Profiles 18
dexamethasone acetate - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
sertraline hydrochloride - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
sertraline hydrochloride - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Morphine + Coloxyl + Senna - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Morphine + Clonazepam - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Furosemide + Tolvaptan - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Dyspnea Therapeutics - Dormant Products 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables
Number of Products Under Development for Dyspnea, H2 2012 6
Products under Development for Dyspnea – Comparative Analysis, H2 2012 7
Number of Products under Investigation by Universities/Institutes, H2 2012 8
Comparative Analysis by Late Stage Development, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Assessment by Monotherapy Products, H2 2012 12
Assessment by Combination Products, H2 2012 13
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Stage and Molecule Type, H2 2012 17
Dyspnea Therapeutics – Dormant Products 25

List of Figures
Number of Products under Development for Dyspnea, H2 2012 6
Products under Development for Dyspnea – Comparative Analysis, H2 2012 7
Products under Investigation by Universities/Institutes, H2 2012 8
Late Stage Products, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Assessment by Monotherapy Products, H2 2012 12
Assessment by Combination Products, H2 2012 13
Assessment by Route of Administration, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Molecule Type, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 17

Customers who bought this item also bought

• Dyspnea - Pipeline Review, H1 2012
• Acute Pain - Pipeline Review, H2 2012
• Dyspnea Global Clinical Trials Review, H1, 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012